CHD2

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

Retrieved on: 
Tuesday, May 23, 2023

STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023.

Key Points: 
  • STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023.
  • The keynote session will highlight how GeneDx’s deeply curated, 20 plus year genomic dataset combined with strong research and development experience of a biopharma partner accelerates drug development programs.
  • The panel will discuss how the company’s partnership with Mahzi Therapeutics has helped advance IND-enabling activities and clinical development for the company’s WWOX and CHD2-related drug candidates.
  • To learn more about partnering with GeneDx for biopharmaceutical, academic research, and patient advocacy collaborations, please visit www.genedx.com/collaborators .

Coalition to Cure CHD2 to Hold First-Ever International Research Symposium and Family Conference

Retrieved on: 
Wednesday, May 3, 2023

ORLANDO, Fla., May 3, 2023 /PRNewswire/ -- Coalition to Cure CHD2 (CCC) is pleased to announce its first-ever international research symposium and family conference to be held on June 2nd – 4th at Disney's Coronado Springs Resort in Lake Buena Vista, Florida.

Key Points: 
  • ORLANDO, Fla., May 3, 2023 /PRNewswire/ -- Coalition to Cure CHD2 (CCC) is pleased to announce its first-ever international research symposium and family conference to be held on June 2nd – 4th at Disney's Coronado Springs Resort in Lake Buena Vista, Florida.
  • Certain changes in the CHD2 gene often result in refractory epilepsy, intellectual and developmental delays, and autism.
  • CCC's upcoming conference will bring together families, researchers, clinicians, and industry partners from all over the world to collaborate on advancing research in CHD2-related disorders.
  • The family conference portion of the event will bring together more than 100 family members and researchers from around the world to discuss and learn about the latest research in CHD2.